Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SMMT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.25
  • 50 Day Moving Average: $7.058
  • 200 Day Moving Average: $7.580
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.53
  • P/E Growth: 0.000
  • Market Cap: $88.86M
  • Outstanding Shares: 12,264,000
  • Beta: 0.91
Additional Links:
Companies Related to Summit Therapeutics PLC:

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.33 (194.42% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetDetails
6/21/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details
6/16/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
6/16/2016Canaccord GenuityReiterated RatingBuyView Rating Details
10/2/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details
4/2/2015JMP SecuritiesInitiated CoverageOutperform$32.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/27/2015Q215($0.06)($0.55)ViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
Current Year EPS Consensus Estimate: $-0.590 EPS
Next Year EPS Consensus Estimate: $-2.050 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
DateHeadline
investors.com logoSummit to include new DMD formulation in PhaseOut trial - Proactive Investors USA & Canada (NASDAQ:SMMT)
www.proactiveinvestors.com - August 9 at 7:47 PM
trustnet.com logoSummit Reports Positive Phase 1 Data and Outlin... (NASDAQ:SMMT)
www.trustnet.com - August 9 at 10:44 AM
finance.yahoo.com logoSummit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid (NASDAQ:SMMT)
finance.yahoo.com - August 9 at 10:44 AM
finance.yahoo.com logo7:04 am Summit Therapeutics reports Phase 1 clinical trial results that show a new formulation of ezutromid 'achieved a greater than six-fold increase in maximum plasma levels in DMD patients ' (NASDAQ:SMMT)
finance.yahoo.com - August 9 at 10:44 AM
publicnow.com logoPositive Phase 1 Data and Outlined Route to Market Strategy for Ezutromid (NASDAQ:SMMT)
www.publicnow.com - August 9 at 10:44 AM
globenewswire.com logoSummit Therapeutics to Present at Canaccord Genuity Growth Conference - GlobeNewswire (press release) (NASDAQ:SMMT)
www.globenewswire.com - August 6 at 10:08 AM
nasdaq.com logoSummit Therapeutics to Present at Canaccord Genuity Growth Conference - Nasdaq (NASDAQ:SMMT)
www.nasdaq.com - August 5 at 7:41 PM
finance.yahoo.com logoSummit Therapeutics to Present at Canaccord Genuity Growth Conference (NASDAQ:SMMT)
finance.yahoo.com - August 5 at 10:32 AM
ftsenews.co.uk logoNew Broker Ratings For Summit Therapeutics Plc (SMMT) - FTSE News (NASDAQ:SMMT)
www.ftsenews.co.uk - July 26 at 7:53 PM
News IconWere Analysts Bullish Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) This Week? - Consumer Eagle (NASDAQ:SMMT)
www.consumereagle.com - July 22 at 7:16 PM
News IconSummit Therapeutics plc : Result of AGM - PharmiWeb.com (press release) (NASDAQ:SMMT)
www.pharmiweb.com - July 19 at 8:12 AM
globenewswire.com logoSummit Therapeutics plc : Result of AGM (NASDAQ:SMMT)
inpublic.globenewswire.com - July 18 at 12:50 PM
ftsenews.co.uk logoSummit Therapeutics Plc (SMMT) Updated Price Targets - FTSE News (NASDAQ:SMMT)
www.ftsenews.co.uk - July 15 at 12:43 PM
News IconHow Analysts Rated Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Last Week? - Consumer Eagle (NASDAQ:SMMT)
www.consumereagle.com - July 13 at 10:21 AM
News IconBullish Chart Formation for Summit Therapeutics PLC (ADR) After Forming Inverse H&S Chart Pattern - Press Telegraph (NASDAQ:SMMT)
presstelegraph.com - July 11 at 12:05 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT) - Fiscal Standard (NASDAQ:SMMT)
www.fiscalstandard.com - July 11 at 12:05 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Summit Therapeutics Plc (SMMT) - Fiscal Standard (NASDAQ:SMMT)
www.fiscalstandard.com - July 6 at 12:06 PM
News IconUK car production up in May, but stability vital, says SMMT - Plastics & Rubber Weekly (NASDAQ:SMMT)
www.prw.com - July 2 at 10:05 AM
News IconSingle market boosts UK car industry (NASDAQ:SMMT)
www.thedailystar.net - July 1 at 7:29 PM
News IconBrexit vote to lead to 'instability' in the car industry (NASDAQ:SMMT)
www.bbc.com - July 1 at 7:29 PM
News IconSingle market boosts United Kingdom auto industry, says SMMT (NASDAQ:SMMT)
newsinfilm.com - July 1 at 7:29 PM
News IconUK car output rises 26% in May, but industry group sees Brexit threat (NASDAQ:SMMT)
europe.autonews.com - July 1 at 7:29 PM
News IconUK automotive reports record £71.6 billion turnover (NASDAQ:SMMT)
www.materialstoday.com - July 1 at 7:29 PM
News IconU.K. Auto Industry’s 2015 Growth Robust, Report Says (NASDAQ:SMMT)
wardsauto.com - July 1 at 7:29 PM
News IconUK car production up in May, but stability vital, says SMMT (NASDAQ:SMMT)
www.prw.com - July 1 at 7:29 PM
News IconRAY MASSEY: Manufacturers plough billions into electric driving with all new cars and vans set to be mains powered by 2040 (NASDAQ:SMMT)
www.thisismoney.co.uk - July 1 at 7:29 PM
tradecalls.org logoJanney Montgomery Scott Initiates Coverage on Summit Therapeutics PLC (ADR) to Buy - Trade Calls (NASDAQ:SMMT)
www.tradecalls.org - June 30 at 7:42 PM
globenewswire.com logoSummit Therapeutics plc : Exercise of Options (NASDAQ:SMMT)
inpublic.globenewswire.com - June 28 at 12:14 PM
fiscalstandard.com logoRecently Issued Stock Ratings For Summit Therapeutics Plc (SMMT) - Fiscal Standard (NASDAQ:SMMT)
www.fiscalstandard.com - June 25 at 11:07 AM
globenewswire.com logoSummit Therapeutics plc : Award of Options (NASDAQ:SMMT)
inpublic.globenewswire.com - June 24 at 10:00 AM
breakingfinancenews.com logoSummit Therapeutics PLC (NASDAQ:SMMT) price target held steady to $0 as issued in a report today by Janney Capital - Breaking Finance News (NASDAQ:SMMT)
breakingfinancenews.com - June 23 at 8:08 PM
investors.com logoSummit uses more than gut instinct to prove C.diff antibiotic's worth (NASDAQ:SMMT)
www.proactiveinvestors.com - June 22 at 7:25 PM
breakingfinancenews.com logoSummit Therapeutics PLC (NASDAQ:SMMT) price target held steady to $0 as issued in a report today by Janney Capital (NASDAQ:SMMT)
breakingfinancenews.com - June 22 at 7:25 PM
News IconSummit Therapeutics PLC (ADR) (SMMT) Is Hot On Sarepta Therapeutics Inc (SRPT)’s DMD Tail (NASDAQ:SMMT)
feedproxy.google.com - June 21 at 2:40 PM
marketexclusive.com logoSummit Therapeutics PLC (ADR) (NASDAQ:SMMT) Is Hot On Sarepta Therapeutics Inc (NASDAQ:SRPT)'s DMD Tail - Market Exclusive (NASDAQ:SMMT)
marketexclusive.com - June 21 at 11:46 AM
publicnow.com logoSummit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection (NASDAQ:SMMT)
www.publicnow.com - June 20 at 12:49 PM
4-traders.com logoSummit Therapeutics : First Patient Enrolled in Summits PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD (NASDAQ:SMMT)
www.4-traders.com - June 18 at 6:35 PM
streetinsider.com logoAyretrade, Inc. (SUMM) Announces Enrollment of First Patient in PhaseOut DMD (NASDAQ:SMMT)
www.streetinsider.com - June 18 at 11:32 AM
globenewswire.com logoSummit Therapeutics plc : Notice of AGM (NASDAQ:SMMT)
inpublic.globenewswire.com - June 17 at 7:11 PM
investors.com logoSummit Therapeutics recruits first DMD phase II trial patient (NASDAQ:SMMT)
www.proactiveinvestors.com - June 17 at 10:07 AM
publicnow.com logoFirst Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMD (NASDAQ:SMMT)
www.publicnow.com - June 17 at 8:19 AM
publicnow.com logoSummit to Present at JMP Securities Life Sciences Conference (NASDAQ:SMMT)
www.publicnow.com - June 16 at 8:39 AM
wsj.com logoSmall British Companies Are Less Wary of an Exit From EU (NASDAQ:SMMT)
www.wsj.com - June 13 at 10:26 AM
investors.com logoSummit Therapeutics to host New York DMD event (NASDAQ:SMMT)
www.proactiveinvestors.com - June 8 at 10:33 AM
publicnow.com logoSummit Therapeutics to Host Utrophin R&D Day 15 June 2016 (NASDAQ:SMMT)
www.publicnow.com - June 8 at 10:18 AM
investors.com logoSarepta surges on new hopes for its DMD drug (NASDAQ:SMMT)
www.proactiveinvestors.com - June 7 at 10:15 AM
News IconSummit Therapeutics Plc (SMMT) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News (NASDAQ:SMMT)
www.sharetrading.news - June 3 at 10:27 AM
investors.com logoSummit set to start dosing in DMD trial in second quarter - Proactive Investors USA & Canada (NASDAQ:SMMT)
www.proactiveinvestors.com - June 2 at 7:57 PM
publicnow.com logoFinancial Results from the First Quarter Ended 30 April 2016 (NASDAQ:SMMT)
www.publicnow.com - June 2 at 1:55 PM
globenewswire.com logoSummit Therapeutics plc : 1st Quarter Results (NASDAQ:SMMT)
inpublic.globenewswire.com - June 2 at 10:39 AM

Social

Summit Therapeutics PLC (NASDAQ:SMMT) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff